Abstract:The diblock copolymer (PEI-PAsp(DIP/MEA)) of branched polyethyleneimine (PEI) and biodegradable poly(2-diisopropylamino/2-mercaptoethylamine) ethyl aspartate (PAsp(DIP/MEA)) was synthesized and assembled into nanovesicles for the co-delivery of cytosine deaminase (CD) gene and 5-fluorocytosine (pCMVCD/5-FC) into glioma cells. The nanovesicle comprises a hydrophilic outerlayer of branched PEI for pCMVCD complexation, a hydrophilic inner cavity for prodrug 5-FC loading, and a pH-sensitive membrane crosslinked by disulfide to prevent drug leakage into the bloodstream-simulating environment with neutral pH and without reducing agent. Yet, once the PPDM (PEI-PAsp(DIP/MEA)) nanovesicle was internalized into cancer cells and entrapped inside lysosomes featuring a low pH (∼5) and enriched reducing agent (∼10 mM GSH), it dissociated as a result of tertiary amine protonation and disulfide bond breakage to release the loaded drug. The in vitro release studies showed that less than 10% of 5-FC was released from the nanovesicle in 24 h at pH 7.4, whereas about 98% of 5-FC was released in the presence of 10 mM GSH at pH 5.0. The prodrug 5-FC was converted into its toxic active metabolite 5-fluorouracil (5-FU) by cytosine deaminase inside C6 glioma cells, owing to the effective CD gene transfection and expression. As a result, the 5-FC/pCMVCD-loaded nanovesicle induced effective apoptosis and generated a significant cytotoxic effect in the cancer cells. Our results indicated that this multifunctional nanovesicle is a promising carrier for the co-delivery of gene and drug or prodrug in cancer therapy.

Correction: Co-delivery of 5-Fluorocytosine and Cytosine Deaminase into Glioma Cells Mediated by an Intracellular Environment-Responsive Nanovesicle

Correction: Facile Preparation of Phospholipid-Amorphous Calcium Carbonate Hybrid Nanoparticles: Toward Controllable Burst Drug Release and Enhanced Tumor Penetration.

Co-delivery of 5-fluorouracil and miRNA-34a mimics by host-guest self-assembly nanocarriers for efficacious targeted therapy in colorectal cancer patient-derived tumor xenografts: Erratum

Codelivery of Doxorubicin and MDR1-siRNA by Mesoporous Silica Nanoparticles-Polymerpolyethylenimine to Improve Oral Squamous Carcinoma Treatment [Corrigendum]

Correction: Radiopharmaceutical-activated silicon naphthalocyanine nanoparticles towards tumor photodynamic therapy

Correction: Oral delivery of a platinum anticancer drug using lipid assisted polymeric nanoparticles

Erratum to “Near-infrared responsive 5-fluorouracil and indocyanine green loaded MPEG-PCL nanoparticle integrated with dissolvable microneedle for skin cancer therapy” [Bioact. Mater. 5 (2020) 542–552]

Correction: Ci et al. Enhanced Delivery of Imatinib into Vaginal Mucosa via a New Positively Charged Nanocrystal-Loaded in Situ Hydrogel Formulation for Treatment of Cervical Cancer. Pharmaceutics 2019, 11, 15

Correction: Enhanced Photoluminescence of Silicon Quantum Dots in the Presence of Both Energy Transfer Enhancement and Emission Enhancement Mechanisms Assisted by the Double Plasmon Modes of Gold Nanorods

Co-Delivery of 5-Fluorocytosine and Cytosine Deaminase into Glioma Cells Mediated by an Intracellular Environment-Responsive Nanovesicle

Correction: Highly sensitive fluorescence quantification of intracellular telomerase activity by repeat G-rich DNA enhanced silver nanoclusters.

Erratum: Author Correction to "Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy" [acta Pharm Sin B (2022) 4224-4234].

Corrigendum: Effective Delivery of siRNA-Loaded Nanoparticles for Overcoming Oxaliplatin Resistance in Colorectal Cancer

Erratum: Author correction to 'Co-delivery of nigericin and decitabine using hexahistidine-metal nanocarriers for pyroptosis-induced immunotherapeutics' [Acta Pharm Sin B 12 (2022) 4458-4471]

Correction: an Oxygen Self-Sufficient NIR-responsive Nanosystem for Enhanced PDT and Chemotherapy Against Hypoxic Tumors

Author Correction to “Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy” [acta Pharm Sin B 12 (2022) 4224–4234]

Correction: Tumor-targeting, enzyme-activated nanoparticles for simultaneous cancer diagnosis and photodynamic therapy

Correction: Bioreducible and acid-labile polydiethylenetriamines with sequential degradability for efficient transgelin-2 siRNA delivery

Correction: Co-delivery of all- trans-retinoic acid enhances the anti-metastasis effect of albumin-bound paclitaxel nanoparticles

Correction: Co-delivery of all- trans -retinoic acid enhances the anti-metastasis effect of albumin-bound paclitaxel nanoparticles